| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of US$ 50/kg
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| product name | Olanzapine |
| CAS NO. | 132539-06-1 |
| Specification | 99% |
| Appearance | light yellow powder |
| packing | 10g/bag |
| MOQ | 10G |
Olanzapine is a new atypical neuroleptic that can bind to dopamine receptors, 5-HT receptors and cholinergic receptors and has an antagonistic effect. Antagonism of D2 receptors is related to the treatment of positive symptoms of schizophrenia; antagonism of 5-HT2A receptors is related to the treatment of negative symptoms of schizophrenia. Unlike clozapine, this product will not cause agranulocytosis, delayed disorders and severe mental depression symptoms. It is well absorbed orally, and food has no effect on its absorption rate. The peak plasma concentration can be reached 5 to 8 hours after oral administration. It is mainly metabolized in the liver, and about 75% of this product is excreted in the urine in the form of metabolites.
| Item | Specification | Test result |
| Appearance | light yellow powder | Conforms |
| Assay | 99% | Conforms |
| Heavy metal | ≤10ppm | Conforms |
| Lead | ≤2.0ppm | Conforms |
| As | ≤2.0ppm | Conforms |
| Ca | ≤1.0ppm | Conforms |
| Me | ≤0.1ppm | Conforms |
| Total aerobic microbial count | ≤1000CFU/g | Conforms |
| Total moulds&yeast count | ≤100CFU/g | Conforms |
| Enterobacterial | ≤10MPN/g | Conforms |
| Salmonella | N.D/25g | Conforms |
| Escherichia coli | N.D/10g | Conforms |
| Staphylococcus aureus | N.D/10g | Conforms |
| Pseudomonas aeruginosa | N.D/10g | Conforms |
| Conclusion: Conform with specification. | ||
It is suitable for the acute and maintenance treatment of schizophrenia and other mental illnesses with severe positive symptoms and/or negative symptoms; it can also relieve common secondary affective symptoms of schizophrenia and related diseases.
The oral starting dose, therapeutic dose and maintenance dose are generally 10 mg/day, and the effective range is 5-20 mg/day. The starting dose for elderly patients is 5 mg per day, and the starting dose for patients with severe renal impairment or moderate liver impairment is also 5 mg per day.
){kind=link}